Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

Santa Barbara – October 13, 2026 -- Rona Therapeutics will receive up to $100 million in upfront and near-term milestone payments from Roche under an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7), with potential for a further $1.06 billion in milestones.

London – October 06, 2026 -- The global cell culture monitoring biosensors market is set to more than double from USD 413.8 million in 2024 to USD 906.56 million by 2032, expanding at a 10.3% compound annual growth rate, according to a new report from Credence Research Inc. Demand is being driven by biologics manufacturers, cell therapy developers and high-throughput research labs shifting away from manual sampling toward continuous, non-invasive monitoring.

Sheridan, Wyo. – October 05, 2026 -- The global in vitro diagnostics (IVD) quality control market is set to climb from $1.7 billion in 2026 to $2.2 billion by 2031, a 5.3% compound annual growth rate, according to a new study by Wissen Research.

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

New York – September 21, 2026 -- Africa's push for greater control over its resources and a stronger voice in global governance took center stage as business leaders, heads of state, and investors gathered for the fifth edition of Unstoppable Africa, held alongside the 81st UN General Assembly session at the Marriott Marquis in Times Square.

South San Francisco, Calif. – September 19, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Las Vegas – – September 15, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.